Financings Of The Fortnight Wonders How Wide-Open Is The Window?
This article was originally published in The Pink Sheet Daily
The beginnings of ominous signs are appearing in the flourishing biotech IPO market. Plus news on recent financings by Foundation Medicine, Arvinas, Moderna Therapeutics and Frazier Healthcare.
You may also be interested in...
VCs Put $15M Into New Start-Up From Proteolix Founder
The biotech, Arvinas, will pursue therapies that degrade proteins, a process that could lead to therapeutic approaches to targets previously thought to be undruggable. The $15 million in venture funding is augmented by $3.5 million from the state of Connecticut.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.